Fig. 7From: Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosineFatty acid oxidation of de novo and relapsed primary AML cells treated with VEN/8-Cl-Ado and VEN/AZA versus control. Fatty acid oxidation of de novo (a) and relapsed (b) primary AML cells treated for 24 h with 10 nM VEN plus 500 nM 8-Cl-Ado or 10 nM VEN plus 5 µM AZABack to article page